NCCN Guidelines&#xae; Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

Breast Cancer

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025

J Natl Compr Canc Netw

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R

doi: 10.6004/jnccn.2025.0053

Genitourinary Cancer

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology

J Natl Compr Canc Netw

Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Ippolito JE, Karnes RJ, Kishan A, Kuettel MR, Lang JM, Lee D, Lotan T, McDonald A, Morgan T, Pessoa R, Rais-Bahrami S, Roach M 3rd, Robin T, Rosenfeld S, Scarpato KR, Shabsigh A, Szmulewitz R, Teply BA, Tward J, Valicenti R, VanderWeele D, Wong JK, Kovach E, Freedman-Cass D

doi: 10.6004/jnccn.2025.0052

Endocrine and Neuroendocrine Tumors (NET)

NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025

J Natl Compr Canc Netw

Haddad RI, Bischoff L, Applewhite M, Bernet V, Blomain E, Brito M, Busaidy NL, Campbell M, DeLozier O, Duh QY, Ehya H, Grady E, Guo T, Haymart M, Hunt JP, Kandeel F, Kotwal A, Lamonica DM, Lorch J, Mandel SJ, Markovina S, Mydlarz W, Nabell L, Raeburn CD, Rezaee R, Ridge JA, Ritter H, Roth MY, Salgado SA, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wirth LJ, Wong RJ, Worden F, Yeh MW, Darlow S, Cassara CJ, Sliker B

doi: 10.6004/jnccn.2025.0033

Gynecologic Cancer

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025

J Natl Compr Canc Netw

Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, Brooks R, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R, Glaser S, Howitt BE, Landrum L, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Nieto K, Nwachukwu C, Podoll M, Rodabaugh K, Salani R, Schorge J, Schuetze S, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Sambandam V

doi: 10.6004/jnccn.2025.0038

Lung, Respiratory and Thoracic Cancer

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025

J Natl Compr Canc Netw

Riely GJ, Wood DE, Aisner DL, Loo BW Jr, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Levy B, Lin J, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Mendez ALR, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yau E, Gregory K, Hang L

doi: 10.6004/jnccn.2025.0043

Gynecologic Cancer

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology

J Natl Compr Canc Netw

Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, Brooks R, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R 2nd, Glaser S, Howitt BE, Kendra K, Landrum L, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Nieto K, Nwachukwu C, Podoll M, Rodabaugh K, Salani R, Schorge J, Schuetze S, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Sambandam V

doi: 10.6004/jnccn.2025.0057

Genitourinary Cancer

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Prostate Cancer Prostatic Dis

Siech C, von Kriegstein H, Wenzel M, Cano Garcia C, Le QC, Tennstedt P, Preisser F, Maurer T, Kriegmair M, Chun FKH, Graefen M, Tilki D, Mandel P

doi: 10.1038/s41391-025-01018-y

Genitourinary Cancer

Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology

Prostate

Madendere S, Esen B, Karaarslan UC, Müdüroğlu M, Veznikli M, Gürses B, Vural M, Baydar DE, Demirkol MO, Kordan Y, Esen T

doi: 10.1002/pros.70073

Genitourinary Cancer

Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

J Natl Compr Canc Netw

Balis F, Green DM, Armstrong A, Aye J, Benedetti D, Brown B, Brown E, Cook S, Desai A, Dhillon J, Fair D, Geynisman DM, Hiniker S, Horst K, Jasty-Rao R, Just M, Kieran K, Lin C, MacEwan I, Martinez-Agosto J, Mullen E, Murphy ES, Pinto N, Ranalli M, Rhee D, Rokitka D, Walz A, Wickiser J, Yoon J, Zapala M, Montgomery S, Sliker B

doi: 10.6004/jnccn.2025.0037

Oncology · Hematology

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

Related content

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology

NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology

Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology